Pharmaceutical compositions with antiflaviviral activity

Abstract

Provided is a method of inhibiting viral replication, including contacting one or more cells that has been infected or contacted with a flavivirus with an effective amount of niclosamide, temoporfin, nitazoxanide, tizoxanide, erythrosin B, methylene blue. Contacting one or more cells that have been infected with a flavivirus may include administering the compound to a mammal, a human, or other subject. The flavivirus may be Dengue virus serotype 1, Dengue virus serotype 2, Dengue virus serotype 3, Dengue virus serotype 4, yellow fever virus, West Nile virus, Zika virus, Japanese encephalitis virus, tick-born encephalitis virus, Powassan virus, St. Louis encephalitis virus, or other flavivirus.

1 - 66 . (canceled) 
     
     
         67 . A method of treating a flavivirus, comprising
 administering to a subject a pharmaceutical composition, wherein the pharmaceutical composition comprises a compound or pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient, wherein the compound is selected from   
       
         
           
           
               
               
           
         
       
     
     
         68 . The method of  claim 67 , wherein the compound is niclosamide. 
     
     
         69 . The method of  claim 68 , wherein the flavivirus comprises a flavivirus selected from one or more of Dengue virus serotype 1, Dengue virus serotype 2, Dengue virus serotype 3, Dengue virus serotype 4, yellow fever virus, West Nile virus, Zika virus, and Japanese encephalitis virus. 
     
     
         70 . The method of  claim 68 , wherein the flavivirus comprises a flavivirus selected from Dengue virus serotype 1, Dengue virus serotype 2, Dengue virus serotype 3, and Dengue virus serotype 4. 
     
     
         71 . The method of  claim 68 , wherein the flavivirus comprises yellow fever virus. 
     
     
         72 . The method of  claim 68 , wherein the flavivirus comprises West Nile virus. 
     
     
         73 . The method of  claim 68 , wherein the flavivirus comprises Zika virus. 
     
     
         74 . The method of  claim 68 , wherein the flavivirus comprises Japanese encephalitis virus. 
     
     
         75 . The method of  claim 67 , wherein administering comprises administering a therapeutically effective amount of the compound to a human subject. 
     
     
         76 . The method of  claim 67 , wherein the compound is Erythrosine B. 
     
     
         77 . The method of  claim 76 , wherein the flavivirus comprises a flavivirus selected from one or more of Dengue virus serotype 1, Dengue virus serotype 2, Dengue virus serotype 3, Dengue virus serotype 4, yellow fever virus, West Nile virus, Zika virus, and Japanese encephalitis virus. 
     
     
         78 . The method of  claim 76 , wherein the flavivirus comprises a flavivirus selected from Dengue virus serotype 1, Dengue virus serotype 2, Dengue virus serotype 3, and Dengue virus serotype 4. 
     
     
         79 . The method of  claim 76 , wherein the flavivirus comprises yellow fever virus. 
     
     
         80 . The method of  claim 76 , wherein the flavivirus comprises West Nile virus. 
     
     
         81 . The method of  claim 76 , wherein the flavivirus comprises Zika virus. 
     
     
         82 . The method of  claim 76 , wherein the flavivirus comprises Japanese encephalitis virus. 
     
     
         83 . The method of  claim 76 , wherein administering comprises administering a therapeutically effective amount of the compound to a human subject. 
     
     
         84 . The method of  claim 67 , wherein the compound is Methylene Blue. 
     
     
         85 . The method of  claim 67 , wherein the subject is a non-human subject. 
     
     
         86 . The method of  claim 67 , wherein the subject is a pregnant human or a human suspected of being pregnant.